database / incretin
Retatrutide
also known as LY3437943
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
Triple GIP/GLP-1/glucagon receptor agonist; primary structure not established in openly indexed chemical records at build time — the field stays null rather than guessed.
Molecular data
| molecular formula | not characterised |
|---|---|
| molecular weight | not characterised |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | not characterised |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Triple agonist at GIP, GLP-1 and glucagon receptors.
Reported targets: GIPR GLP-1R GCGR
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| weight loss | The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-H… Clinical pharmacology in drug development 2026 |
| glycaemic control | Retatrutide in type 2 diabetes mellitus and obesity: an overview Expert review of clinical pharmacology 2026 |
| hepatic fat reduction | Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight … Preprints.org 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT06808802 | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healt | COMPLETED | PHASE1 |
| NCT06354660 | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and I | COMPLETED | PHASE3 |
| NCT05611957 | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | COMPLETED | PHASE1 |
| NCT06003465 | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection De | COMPLETED | PHASE1 |
| NCT06297603 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderat | ACTIVE_NOT_RECRUITING | PHASE3 |
Literature (8)
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities — Clinical pharmacology in drug development 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41545327 · DOI 10.1002/cpdd.70001
Retatrutide in type 2 diabetes mellitus and obesity: an overview — Expert review of clinical pharmacology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41785010 · DOI 10.1080/17512433.2026.2642415
Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202608.1193.v1
Inotropic effects of retatrutide in isolated human atrial preparations — Naunyn-Schmiedeberg's archives of pharmacology 2026
Retatrutide (LY3437943) was developed as a drug to treat type 2 diabetes and obesity. Retatrutide, a not endogenously occurring peptide, stimulated the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R) in cell cultures; increased the activity of adenylyl cyclases (AC); and thus augmented the 3',5' cyclic adenosine monophosphate (cAMP) levels. We tested the hypothesis that retatrutide increased force of contraction (FOC) in human right atrial preparations (HAP) from adult patients. HAP were obtained during open heart surgery from patients who suffered from severe coronary heart disease. We noted that cumulatively applied retatrutide starting at 10 nM (up to 100 nM the highest concentration tested) elevated FOC in HAP in a concentration- and time-dependent manner. In the additional presence of…
open access ↗ · PMID 40613938 · DOI 10.1007/s00210-025-04421-3
Retatrutide Treatment in Streptozotocin-Induced Diabetic Rats: Renal Inflammatory Cytokines, HIF‑1α Signalling, and Histopathological Injury Profile — Research Square 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.21203/rs.3.rs-10191227/v1
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats — Behavioural brain research 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42385950 · DOI 10.1016/j.bbr.2026.116343
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice — iScience 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42630988 · DOI 10.1016/j.isci.2026.117174
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes — Diabetes, obesity & metabolism 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42608321 · DOI 10.1111/dom.71200
Related
Semaglutide
incretin · 8 citations
Tirzepatide
incretin · 8 citations
Liraglutide
incretin · 8 citations
Exenatide
incretin · 8 citations
Glucagon
hormone · 8 citations
GLP-1 (7-37)
incretin · 8 citations